2020 | Proceedings of the National Academy of Science | Bhargava H.K., Tabata K., Byck J.M., Hamasaki M., Farrell D.P., Anishchenko I., DiMaio F., Im Y.J., Yoshimori T., Hurley J.H.
We report the novel atomic structure of autophagy inhibitor Rubicon bound to GTPase Rab7. Our work provides a roadmap to block Rubicon localization and activity in order to upregulate autophagy, a major drug development goal.PDF Journal Website PDB Entry
2020 | Clinical Cancer Research | Bhargava H.K., Leo, P., Elliott, R., Janowcyzk, A., Whitney, J., Gupta, S., Fu, P., Yamoah, K., Rebbeck, T., Feldman, D., Lal, P., Madabhushi, A.
We developed computer vision and machine learning to predict prostate cancer recurrence risk based on quantitative measurements of the intratumoral stroma computed from digitized H&E images.PDF Journal Website
2021 | Nature Chemical Biology | Deo, C.*, Abdelfattah, A.S.*, Bhargava, H.K., Berro, A., Falco, N., Moeyaert, B., Chupanova, M., Lavis, L.D., Schreiter, E.R.
We introduce a new platform for ‘chemigenetic’ fluorescent indicators, utilizing the self-labeling HaloTag protein conjugated to environmentally sensitive synthetic fluorophores. This approach affords bright, far-red calcium and voltage sensors with highly tunable photophysical and chemical properties, which can reliably detect single action potentials in neurons.PDF Journal Website
2019 | American Journal of Clinical Pathology | Arriola, A., Farahani, S., Bhargava, H.K., Guzzo, T., Brooks, J., Lal, P.
This study comprehensively reviews programmed death 1 receptor (PD-1)–positive and CD8+ tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on tumor epithelium (TE).PDF Journal Website